Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.43 |
| ▸ | RBP4 | P02753 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 2/20 | 0.39 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4562325 | 0.93 | TRPV1 (0.40) | TRPV1RBP4NPSR1MAPK1 | |
| SCHEMBL2384209 | 0.90 | TRPV1 (0.40) | TRPV1RBP4KDM4ENPSR1KIT | |
| SCHEMBL2385822 | 0.89 | TRPV1 (0.46) | TRPV1RBP4KDM4ENPSR1 | |
| SCHEMBL2386446 | 0.87 | ALDH1A1 (0.38) | TRPV1RBP4NPSR1MAPTKIT | |
| SCHEMBL2385038 | 0.87 | TRPV1 (0.48) | TRPV1KDM4ENPSR1MAPTKIT | |
| SCHEMBL2383249 | 0.86 | TRPV1 (0.55) | TRPV1KDM4ENPSR1MAPTKIT | |
| SCHEMBL2385265 | 0.85 | TRPV1 (0.45) | TRPV1KDM4ENPSR1MAPTKIT | |
| SCHEMBL2383530 | 0.85 | MAPT (0.45) | TRPV1RBP4KDM4ENPSR1MAPT | |
| SCHEMBL2384448 | 0.85 | TRPV1 (0.46) | TRPV1KDM4ENPSR1MAPTKIT | |
| SCHEMBL2733022 | 0.82 | TRPV1 (0.45) | TRPV1RBP4KDM4ENPSR1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | claimed |
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | TIE1, TEK, KDR | TRPV1 4108/4885RBP4 2966/4885KDM4E 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.